BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 9150150)

  • 1. BRCA2 in American families with four or more cases of breast or ovarian cancer: recurrent and novel mutations, variable expression, penetrance, and the possibility of families whose cancer is not attributable to BRCA1 or BRCA2.
    Schubert EL; Lee MK; Mefford HC; Argonza RH; Morrow JE; Hull J; Dann JL; King MC
    Am J Hum Genet; 1997 May; 60(5):1031-40. PubMed ID: 9150150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families.
    Levy-Lahad E; Catane R; Eisenberg S; Kaufman B; Hornreich G; Lishinsky E; Shohat M; Weber BL; Beller U; Lahad A; Halle D
    Am J Hum Genet; 1997 May; 60(5):1059-67. PubMed ID: 9150153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and ovarian cancer.
    Schubert EL; Mefford HC; Dann JL; Argonza RH; Hull J; King MC
    Genet Test; 1997; 1(1):41-6. PubMed ID: 10464624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families.
    Friedman LS; Szabo CI; Ostermeyer EA; Dowd P; Butler L; Park T; Lee MK; Goode EL; Rowell SE; King MC
    Am J Hum Genet; 1995 Dec; 57(6):1284-97. PubMed ID: 8533757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 mutation analysis of 208 Ashkenazi Jewish women with ovarian cancer.
    Moslehi R; Chu W; Karlan B; Fishman D; Risch H; Fields A; Smotkin D; Ben-David Y; Rosenblatt J; Russo D; Schwartz P; Tung N; Warner E; Rosen B; Friedman J; Brunet JS; Narod SA
    Am J Hum Genet; 2000 Apr; 66(4):1259-72. PubMed ID: 10739756
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutational analyses of BRCA1 and BRCA2 in Ashkenazi and non-Ashkenazi Jewish women with familial breast and ovarian cancer.
    Shiri-Sverdlov R; Oefner P; Green L; Baruch RG; Wagner T; Kruglikova A; Haitchick S; Hofstra RM; Papa MZ; Mulder I; Rizel S; Bar Sade RB; Dagan E; Abdeen Z; Goldman B; Friedman E
    Hum Mutat; 2000 Dec; 16(6):491-501. PubMed ID: 11102978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequency of BRCA1 and BRCA2 germline mutations in Japanese breast cancer families.
    Ikeda N; Miyoshi Y; Yoneda K; Shiba E; Sekihara Y; Kinoshita M; Noguchi S
    Int J Cancer; 2001 Jan; 91(1):83-8. PubMed ID: 11149425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for detecting germline BRCA1 and BRCA2 founder mutations in Ashkenazi Jewish women with breast or ovarian cancer.
    Hodgson SV; Heap E; Cameron J; Ellis D; Mathew CG; Eeles RA; Solomon E; Lewis CM
    J Med Genet; 1999 May; 36(5):369-73. PubMed ID: 10353781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two distinct origins of a common BRCA1 mutation in breast-ovarian cancer families: a genetic study of 15 185delAG-mutation kindreds.
    Berman DB; Wagner-Costalas J; Schultz DC; Lynch HT; Daly M; Godwin AK
    Am J Hum Genet; 1996 Jun; 58(6):1166-76. PubMed ID: 8651293
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 genes: role in hereditary breast and ovarian cancer in Italy.
    Santarosa M; Dolcetti R; Magri MD; Crivellari D; Tibiletti MG; Gallo A; Tumolo S; Della Puppa L; Furlan D; Boiocchi M; Viel A
    Int J Cancer; 1999 Sep; 83(1):5-9. PubMed ID: 10449599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recurrent BRCA2 6174delT mutations in Ashkenazi Jewish women affected by breast cancer.
    Neuhausen S; Gilewski T; Norton L; Tran T; McGuire P; Swensen J; Hampel H; Borgen P; Brown K; Skolnick M; Shattuck-Eidens D; Jhanwar S; Goldgar D; Offit K
    Nat Genet; 1996 May; 13(1):126-8. PubMed ID: 8673092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The founder mutations 185delAG and 5382insC in BRCA1 and 6174delT in BRCA2 appear in 60% of ovarian cancer and 30% of early-onset breast cancer patients among Ashkenazi women.
    Abeliovich D; Kaduri L; Lerer I; Weinberg N; Amir G; Sagi M; Zlotogora J; Heching N; Peretz T
    Am J Hum Genet; 1997 Mar; 60(3):505-14. PubMed ID: 9042909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A family with three germline mutations in BRCA1 and BRCA2.
    Liede A; Metcalfe K; Offit K; Brown K; Miller S; Narod SA; Moslehi R
    Clin Genet; 1998 Sep; 54(3):215-8. PubMed ID: 9788724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
    HĂ„kansson S; Johannsson O; Johansson U; Sellberg G; Loman N; Gerdes AM; Holmberg E; Dahl N; Pandis N; Kristoffersson U; Olsson H; Borg A
    Am J Hum Genet; 1997 May; 60(5):1068-78. PubMed ID: 9150154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High throughput fluorescence-based conformation-sensitive gel electrophoresis (F-CSGE) identifies six unique BRCA2 mutations and an overall low incidence of BRCA2 mutations in high-risk BRCA1-negative breast cancer families.
    Ganguly T; Dhulipala R; Godmilow L; Ganguly A
    Hum Genet; 1998 May; 102(5):549-56. PubMed ID: 9654203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic.
    Shih HA; Couch FJ; Nathanson KL; Blackwood MA; Rebbeck TR; Armstrong KA; Calzone K; Stopfer J; Seal S; Stratton MR; Weber BL
    J Clin Oncol; 2002 Feb; 20(4):994-9. PubMed ID: 11844822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic testing in an ethnically diverse cohort of high-risk women: a comparative analysis of BRCA1 and BRCA2 mutations in American families of European and African ancestry.
    Nanda R; Schumm LP; Cummings S; Fackenthal JD; Sveen L; Ademuyiwa F; Cobleigh M; Esserman L; Lindor NM; Neuhausen SL; Olopade OI
    JAMA; 2005 Oct; 294(15):1925-33. PubMed ID: 16234499
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A low frequency of non-founder BRCA1 mutations in Ashkenazi Jewish breast-ovarian cancer families.
    Phelan CM; Kwan E; Jack E; Li S; Morgan C; Aubé J; Hanna D; Narod SA
    Hum Mutat; 2002 Nov; 20(5):352-7. PubMed ID: 12402332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.